MentalHealthDaily

Rexulti (Brexpiprazole) Withdrawal Symptoms: What You Should Know

Rexulti (Brexpiprazole) is an atypical antipsychotic that is most commonly utilized as a pharmacologic intervention for the management of schizophrenia, and in some cases, as an add-on (adjunct) treatment for refractory major depressive disorder. Throughout the central nervous system, the medication exerts neurophysiologic effects across dopaminergic, serotonergic, noradrenergic, and histaminergic targets. Receptor sites most targeted …

Rexulti (Brexpiprazole) & Weight Gain: Will It Make You Fat?

by GLOOM

Rexulti (Brexpiprazole), is an atypical antipsychotic that was jointly developed by pharmaceutical companies Otsuka and Lundbeck. In 2015, the FDA approved Rexulti for the treatment of schizophrenia and major depressive disorder (as an adjunct). Rexulti functions as a “serotonin-dopamine activity modulator” (SDAM) and is intended to be a superior successor to the antipsychotic Abilify (Aripiprazole) …

Rexulti Side Effects & Adverse Reactions (List)

by GLOOM

Rexulti (Brexpiprazole), is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia and major depressive disorder (as an adjunct). The drug was engineered via collaboration between pharmaceutical companies Otsuka and Lundbeck and is considered the successor to Abilify (aripiprazole), a formerly top-selling antipsychotic medication with an expired patent. Although Rexulti is marketed …

Rexulti (Brexpiprazole) Approved For Schizophrenia & Depression (Adjunct)

by GLOOM

Rexulti (Brexpiprazole) is a drug that was approved July 10, 2015 for the treatment of schizophrenia and as an adjunctive option for major depressive disorder. In clinical trials it was referred to as the chemical “OPC-34712” and is being marketed as a superior successor to Abilify (Aripiprazole) due to the fact that Abilify’s patent expired …